Platycodin D from Platycodon grandiflorus as an anticancer lead: signaling mechanisms, active derivatives, bioanalytical quantification and translational ADME/PK.

Platycodin D is a triterpenoid saponin from Platycodon grandiflorus (balloon flower) that has emerged as a promising natural anticancer lead. This review synthesizes current evidence on its antitumor pharmacology and translational development, with emphasis on signaling mechanisms, active derivatives, bioanalytical quantification, and ADME/pharmacokinetics. Platycodin D suppresses tumor growth by engaging multiple cancer hallmarks, including induction of apoptosis and other programmed cell-death programs, inhibition of proliferation, and attenuation of invasion and metastasis. These effects are mediated, in part, through modulation of key oncogenic and stress-response pathways such as PI3K/Akt, NF-κB and MAPK, alongside broader impacts on inflammatory and immune-regulatory networks. We further summarize structure-activity relationships and reported semisynthetic/natural analogs that inform lead optimization, as well as available evidence for chemosensitization and reversal of drug-resistance phenotypes in preclinical models. In addition, we overview current LC-MS/MS-based methods for bioanalysis of platycodin D in biological matrices and critically discuss major translational liabilities, including low oral bioavailability and ADME determinants (e.g., limited permeability, efflux, and metabolism), together with enabling formulation and delivery strategies. Collectively, the data support platycodin D as a multi-target anticancer scaffold while underscoring the need for rigorous in vivo validation, standardized pharmacokinetic characterization, safety evaluation, and well-designed clinical studies to define its therapeutic potential.